JP2017514909A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514909A5 JP2017514909A5 JP2017510455A JP2017510455A JP2017514909A5 JP 2017514909 A5 JP2017514909 A5 JP 2017514909A5 JP 2017510455 A JP2017510455 A JP 2017510455A JP 2017510455 A JP2017510455 A JP 2017510455A JP 2017514909 A5 JP2017514909 A5 JP 2017514909A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- acute
- leukemia
- thieno
- triazolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 43
- 239000003814 drug Substances 0.000 claims description 38
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 26
- 239000007962 solid dispersion Substances 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 19
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 16
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 14
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 14
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 9
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 6
- 239000002243 precursor Substances 0.000 claims description 6
- GNMUEVRJHCWKTO-FQEVSTJZSA-N 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NC1=CC=C(O)C=C1 GNMUEVRJHCWKTO-FQEVSTJZSA-N 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- -1 (S) -2- [4- (4-chlorophenyl) -2,3, 9-Trimethyl-6H-thieno [3,2-f] [1,2,4] triazolo [4,3-a] [1,4] diazepin-6-yl] -N- (4-hydroxyphenyl) acetamide compound Chemical class 0.000 claims description 4
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims description 4
- 230000005856 abnormality Effects 0.000 claims description 4
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 4
- 230000009477 glass transition Effects 0.000 claims description 4
- 230000035800 maturation Effects 0.000 claims description 4
- 230000000306 recurrent effect Effects 0.000 claims description 4
- 230000002068 genetic effect Effects 0.000 claims description 3
- 208000016557 Acute basophilic leukemia Diseases 0.000 claims description 2
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims description 2
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 claims description 2
- 208000016585 Acute panmyelosis with myelofibrosis Diseases 0.000 claims description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 2
- 208000033775 Basophilic Acute Leukemia Diseases 0.000 claims description 2
- 208000023611 Burkitt leukaemia Diseases 0.000 claims description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 2
- 206010008583 Chloroma Diseases 0.000 claims description 2
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims description 2
- 206010058314 Dysplasia Diseases 0.000 claims description 2
- 206010014950 Eosinophilia Diseases 0.000 claims description 2
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims description 2
- 208000036566 Erythroleukaemia Diseases 0.000 claims description 2
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 claims description 2
- 208000008601 Polycythemia Diseases 0.000 claims description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 201000011176 T-cell adult acute lymphocytic leukemia Diseases 0.000 claims description 2
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims description 2
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims description 2
- 208000021841 acute erythroid leukemia Diseases 0.000 claims description 2
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 claims description 2
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 claims description 2
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 230000002559 cytogenic effect Effects 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 230000001973 epigenetic effect Effects 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 239000003862 glucocorticoid Substances 0.000 claims description 2
- 210000003714 granulocyte Anatomy 0.000 claims description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 2
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 2
- 201000005987 myeloid sarcoma Diseases 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims 36
- 208000026661 Acute myeloid leukemia with 11q23 abnormalities Diseases 0.000 claims 1
- CWHGYLGCKHZVHG-UHFFFAOYSA-N CC(=O)NC1=CC=C(C=C1)O.O.O Chemical compound CC(=O)NC1=CC=C(C=C1)O.O.O CWHGYLGCKHZVHG-UHFFFAOYSA-N 0.000 claims 1
- HMKHWYHCDUFAJR-UHFFFAOYSA-N acetamide;dihydrate Chemical compound O.O.CC(N)=O HMKHWYHCDUFAJR-UHFFFAOYSA-N 0.000 claims 1
- 239000003697 methyltransferase inhibitor Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 34
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 7
- 125000005843 halogen group Chemical group 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 239000003968 dna methyltransferase inhibitor Substances 0.000 description 1
- 230000005861 gene abnormality Effects 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461987822P | 2014-05-02 | 2014-05-02 | |
| US61/987,822 | 2014-05-02 | ||
| US201461990465P | 2014-05-08 | 2014-05-08 | |
| US61/990,465 | 2014-05-08 | ||
| US201462012128P | 2014-06-13 | 2014-06-13 | |
| US201462012135P | 2014-06-13 | 2014-06-13 | |
| US62/012,135 | 2014-06-13 | ||
| US62/012,128 | 2014-06-13 | ||
| US201462080771P | 2014-11-17 | 2014-11-17 | |
| US201462080804P | 2014-11-17 | 2014-11-17 | |
| US62/080,804 | 2014-11-17 | ||
| US62/080,771 | 2014-11-17 | ||
| US201462086456P | 2014-12-02 | 2014-12-02 | |
| US62/086,456 | 2014-12-02 | ||
| PCT/US2015/028891 WO2015168621A1 (en) | 2014-05-02 | 2015-05-01 | Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017514909A JP2017514909A (ja) | 2017-06-08 |
| JP2017514909A5 true JP2017514909A5 (https=) | 2018-06-14 |
Family
ID=54359398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017510455A Pending JP2017514909A (ja) | 2014-05-02 | 2015-05-01 | チエノトリアゾロジアゼピン化合物を用いる急性骨髄性白血病及び／又は急性リンパ芽球性白血病の治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9956228B2 (https=) |
| EP (1) | EP3137085A4 (https=) |
| JP (1) | JP2017514909A (https=) |
| KR (1) | KR20160145833A (https=) |
| CN (1) | CN107073014A (https=) |
| AU (1) | AU2015252844A1 (https=) |
| CA (1) | CA2947601A1 (https=) |
| MX (1) | MX2016014301A (https=) |
| RU (1) | RU2016146099A (https=) |
| WO (1) | WO2015168621A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX366703B (es) | 2013-03-15 | 2019-07-22 | Incyte Holdings Corp | Heterociclos tricíclicos como inhibidores de la proteína bet. |
| AR096837A1 (es) | 2013-07-08 | 2016-02-03 | Incyte Corp | Heterociclos tricíclicos como inhibidores de proteínas bet |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| EA034972B1 (ru) | 2014-04-23 | 2020-04-13 | Инсайт Корпорейшн | 1h-пирроло[2,3-c]пиридин-7(6h)-оны в качестве ингибиторов белков bet |
| US9527864B2 (en) | 2014-09-15 | 2016-12-27 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| TW201722966A (zh) | 2015-10-29 | 2017-07-01 | 英塞特公司 | Bet蛋白質抑制劑之非晶固體形式 |
| KR102643344B1 (ko) | 2016-06-20 | 2024-03-07 | 인사이트 코포레이션 | Bet 저해제의 결정질 고체 형태 |
| EP3615020B1 (en) * | 2017-04-26 | 2024-04-10 | University of Cincinnati | Methods, agents, and compositions for the treatment of acute myeloid leukemia |
| MX2020013608A (es) | 2018-06-13 | 2021-03-09 | Worg Pharmaceuticals Hangzhou Co Ltd | Preparacion de derivados de triazepina condensados y su uso como inhibidores de bet. |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| KR20240028420A (ko) | 2021-06-08 | 2024-03-05 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 항암 화합물 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001095912A1 (fr) | 2000-06-16 | 2001-12-20 | Mitsubishi Pharma Corporation | Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph |
| EP1170008A1 (en) * | 2000-07-07 | 2002-01-09 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Valproic acid and derivatives thereof as histone deacetylase inhibitors |
| ATE545408T1 (de) * | 2004-08-10 | 2012-03-15 | Talon Therapeutics Inc | Zusammensetzungen und verfahren zur behandlung von leukämie |
| BRPI0807812A2 (pt) * | 2007-02-15 | 2020-06-23 | Novartis Ag | Combinações de lbh589 com outros agentes terapêuticos para tratar câncer |
| WO2009084693A1 (ja) * | 2007-12-28 | 2009-07-09 | Mitsubishi Tanabe Pharma Corporation | 抗癌剤 |
| NZ589719A (en) * | 2008-06-09 | 2012-08-31 | Cyclacel Ltd | Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine |
| PL2902030T3 (pl) * | 2010-05-14 | 2017-07-31 | Dana-Farber Cancer Institute, Inc. | Związki tienotriazolodiazepinowe do leczenia nowotworu |
| MX354217B (es) * | 2010-05-14 | 2018-02-19 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| CA2827673C (en) * | 2011-02-18 | 2020-10-27 | Novartis Pharma Ag | Mtor/jak inhibitor combination therapy |
| DE102011082013A1 (de) * | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
| MX2014015986A (es) | 2012-06-25 | 2016-02-11 | Oncoethix Gmbh | Metodo para tratar linfoma utilizando compuestos de tienotriazolodiazepina. |
| CN104968334B (zh) | 2012-09-28 | 2018-09-14 | 翁科埃斯克斯有限公司 | 包含噻吩并三唑并二氮杂卓化合物的药物制剂 |
| WO2015014998A1 (en) * | 2013-08-01 | 2015-02-05 | Oncoethix Sa | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
| CN105960239A (zh) * | 2013-11-27 | 2016-09-21 | 翁科埃斯克斯有限公司 | 利用含有噻吩并三唑并二氮杂*化合物的药物制剂治疗白血病的方法 |
| CN107427524A (zh) * | 2014-08-28 | 2017-12-01 | 翁科埃斯克斯有限公司 | 利用包含噻吩并三唑并二氮杂*化合物的药物组合物治疗急性髓细胞白血病或急性淋巴性白血病的方法 |
-
2015
- 2015-05-01 CN CN201580036473.XA patent/CN107073014A/zh active Pending
- 2015-05-01 AU AU2015252844A patent/AU2015252844A1/en not_active Abandoned
- 2015-05-01 MX MX2016014301A patent/MX2016014301A/es unknown
- 2015-05-01 RU RU2016146099A patent/RU2016146099A/ru not_active Application Discontinuation
- 2015-05-01 KR KR1020167033946A patent/KR20160145833A/ko not_active Withdrawn
- 2015-05-01 US US15/308,540 patent/US9956228B2/en not_active Expired - Fee Related
- 2015-05-01 EP EP15785547.9A patent/EP3137085A4/en not_active Withdrawn
- 2015-05-01 CA CA2947601A patent/CA2947601A1/en not_active Abandoned
- 2015-05-01 WO PCT/US2015/028891 patent/WO2015168621A1/en not_active Ceased
- 2015-05-01 JP JP2017510455A patent/JP2017514909A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514909A5 (https=) | ||
| AU2022241561B2 (en) | Dosage form compositions comprising an inhibitor of Bruton's tyrosine kinase | |
| RU2016146099A (ru) | Способ лечения острого миелоидного лейкоза и/или острого лимфобластного лейкоза с помощью тиенотриазолодиазепиновых соединений | |
| JP2016538310A5 (https=) | ||
| JP2015531747A5 (https=) | ||
| JP2017517579A5 (https=) | ||
| HRP20231533T1 (hr) | Kristalni oblici od (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f][1,2,4 ]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina i postupci priprave | |
| AU2024353274A1 (en) | Combinations of wx-001 or derivatives thereof with a kras g12c inhibitor for use in the treatment of cancer | |
| TW201815798A (zh) | 苯并氧氮呯噁唑啶酮化合物及其製備方法 | |
| JP2019512535A5 (https=) | ||
| JP2015503613A5 (https=) | ||
| WO2018233620A1 (zh) | SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途 | |
| CN105960239A (zh) | 利用含有噻吩并三唑并二氮杂*化合物的药物制剂治疗白血病的方法 | |
| JP2016529246A5 (https=) | ||
| JP2008517913A5 (https=) | ||
| JP2012524089A5 (https=) | ||
| JP2017514907A5 (https=) | ||
| CN106852120A (zh) | 利用噻吩并三唑并二氮杂*化合物治疗三阴性乳腺癌的方法 | |
| JP2016525563A5 (https=) | ||
| CN111511745A (zh) | 吡唑并[1,5-a][1,3,5]三嗪-2-胺类衍生物、其制备方法及其在医药上的应用 | |
| CA2584303A1 (en) | Novel heterocycles | |
| JP2019512534A5 (https=) | ||
| WO2017206962A1 (zh) | Flt3激酶的新型抑制剂及其用途 | |
| WO2015078928A1 (en) | Method of treating non-small-cell lung cancer using pharmaceutical formulation containing thienotriazolodiazepine compounds | |
| CN111718349A (zh) | 含氟吡唑并嘧啶化合物和药物组合物及其应用 |